Abstract 1741P
Background
Little research has been made on real-world clinical scenarios of potential ethical relevance in specific cancers, including sarcomas.
Methods
Our sarcoma multidisciplinary tumor board (MTB) discusses all cases of adult patients with soft tissue sarcomas, bone sarcomas and GIST selected by the clinical oncologist in charge as deserving a multidisciplinary discussion. Over a 1-yr interval, all discussed cases were filtered by a group of senior and junior experts in bioethics and sarcomas in order to highlight those of potential ethical concern, i.e. whenever a problematic conflict could be envisaged between the ethical principles of beneficence, non-maleficence, autonomy and justice. These cases were retrospectively reviewed, and an attempt was made to group them into distinct ethical scenarios.
Results
From January to December 2023, 327 sarcoma cases were discussed by our MTB. Forty-one cases (12%) were prospectively or retrospectively selected as carrying possible ethical relevance. Among them, the following clinical scenarios were identified (total >100% since scenarios are not mutually exclusive): 1. ethically-relevant uncertainty about a diagnostic/treatment option (46%); 2. best treatment option at a high-risk of complications of problematic acceptance (5%); 3. controversial futility (17%); 4. problematic trade-off between quality and quantity of life (17%); 5. problematic management of patient dissent (15%); 6. clinical disagreement of potential ethical concern (10%); 7. problematic communication of all clinical implications to the individual patient (15%). 8. controversial enrolment of an eligible patient in a clinical trial or trial requirements of ethical concern in the individual patient (2%); 9. best clinical option conflicting with social/economical constraints (0.3%); 10. bedside rationing, or perception of implicit rationing of scarce resources (2%).
Conclusions
A non-negligible incidence of ethically-relevant clinical cases was observed. Sarcoma centres should be aware of specific ethical implications possibly affecting their everyday practice. Paradigmatic clinical cases for each of the ten clinical scenarios proposed herein will be presented.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1773P - Genomic and transcriptomic analysis of chondrosarcomas to explore new potential treatment options
Presenter: Konstantin Zirov
Session: Poster session 06
1774P - Immunological-molecular profiling of chondrosarcoma (ChS)
Presenter: Piotr Rutkowski
Session: Poster session 06
1775P - Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas
Presenter: Evan Rosenbaum
Session: Poster session 06
1776P - Targeting B7H3 biomimetic nanoparticles for strengthening osteosarcoma photodynamic therapy through aggravating DNA damage
Presenter: Tianqi Luo
Session: Poster session 06
1777P - Molecular profiling from next-generation sequencing (NGS) reveals new potential therapeutic targets in patients with pediatric-type sarcomas
Presenter: Anthony Conley
Session: Poster session 06
1778P - Clear cell sarcomas (CCS) express Gp100: A novel immune target for a bispecific T cell engager
Presenter: Elise Nassif Haddad
Session: Poster session 06
1779P - Deep learning tertiary lymphoid structures detection on HES/H&E slides and association to survival outcome in sarcoma
Presenter: Lucile Vanhersecke
Session: Poster session 06
1780P - Homologous recombination pathway in sarcomas: A novel opportunity of therapy?
Presenter: María del Carmen Garijo Martínez
Session: Poster session 06